MedTrace Logo

AZD0837 Extended Release (ER) Japan Study

NCT00904800 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2009-07-13

No results posted yet for this study

Summary

This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.

Conditions

  • Healthy

Interventions

DRUG

AZD0837

tablet, oral, once daily, 1+5 days

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Hiroyuki Fukase, MD, PhD · CPC Clinic, Medipolis Medical Research Institute, Kagoshima, Japan

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Completion
2009-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904800 on ClinicalTrials.gov